Sergio Juárez-Méndez

Dr. Sergio Juárez-Méndez

Instituto Nacional de Pediatria, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2006 in Synapse
Verified
Journal Article
Closed access
PDF file
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
RCRosalba Carretero
Rosalba Carretero
RMRubelia Martínez‐Tellez
Rubelia Martínez‐Tellez
ASAdriana B. Silva‐Gómez
Adriana B. Silva‐Gómez
GFGonzalo Flores
Gonzalo Flores

5 September 2013 in Journal of Ovarian Research
Verified
Journal Article
Open access
PDF file
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
ADALEJANDRO ZENTELLA DEHESA
ALEJANDRO ZENTELLA DEHESA
VVVanessa Villegas-Ruíz
Vanessa Villegas-Ruíz
ÓPÓscar Alberto Pérez-González
Óscar Alberto Pérez-González
MSMauricio Salcedo
Mauricio Salcedo
JMJosé Moreno
José Moreno
Background: Studies of alternative mRNA splicing (AS) in health and disease have yet to yield the complete picture of protein diversity and its role in physiology and pathology. Some forms of cancer appear to be associated to certain alternative mRNA splice variants, but their role in the cancer development and outcome is unclear.Methods: We examined AS profiles by means of whole genome exon expression microarrays (Affymetrix GeneChip 1.0) in ovarian tumors and ovarian cancer-derived cell lines, compared to healthy ovarian tissue. Alternatively spliced genes expressed predominantly in ovarian tumors and cell lines were confirmed by RT-PCR.Results: Among several significantly overexpressed AS genes in malignant ovarian tumors and ovarian cancer cell lines, the most significant one was that of the zinc finger protein ZNF695, with two previously unknown mRNA splice variants identified in ovarian tumors and cell lines. The identity of ZNF695 AS variants was confirmed by cloning and sequencing of the amplicons obtained from ovarian cancer tissue and cell lines.Conclusions: Alternative ZNF695 mRNA splicing could be a marker of ovarian cancer with possible implications on its pathogenesis.

1 January 2014
Verified
Journal Article
Closed access
VVVanessa Villegas-Ruíz
Vanessa Villegas-Ruíz
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
OPOscar A. Perez-Gonzalez
Oscar A. Perez-Gonzalez
HAHugo Arreola
Hugo Arreola
LPLucero Paniagua-Garcia
Lucero Paniagua-Garcia
MSMauricio Salcedo
Mauricio Salcedo

7 January 2010 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
RPRaúl Peralta
Raúl Peralta
MBMichael Baudis
Michael Baudis
GVGuelaguetza Vazquez
Guelaguetza Vazquez
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
RORocio Ortiz-Lopez
Rocio Ortiz-Lopez
MSMauricio Salcedo
Mauricio Salcedo

16 September 2019 in Genes
Verified
Journal Article
Open access
PDF file
RRRicardo De la Rosa
Ricardo De la Rosa
VVVanessa Villegas-Ruíz
Vanessa Villegas-Ruíz
MCMarcela Concepción Caballero-Palacios
Marcela Concepción Caballero-Palacios
EPEleazar Israel Pérez-López
Eleazar Israel Pérez-López
CMChiharu Murata
Chiharu Murata
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
B-cell acute lymphoblastic leukemia is the most commonly diagnosed childhood malignancy worldwide; more than 50% of these cases are diagnosed in Mexico. Although the five-year survival rate is >80%, 30% of patients experience relapse with poor prognosis. Cancer-associated gene expression profiles have been identified in several malignancies, and some transcripts have been used to predict disease prognosis. The human transcriptome is incompletely elucidated; moreover, more than 80% of transcripts can be processed via alternative splicing (AS), which increases transcript and protein diversity. The human transcriptome is divided; coding RNA accounts for ~2%, and the remaining 98% is noncoding RNA. Noncoding RNA can undergo AS, promoting the diversity of noncoding transcripts. We designed specific primers to amplify previously reported alternative transcript variants of ZNF695 and showed that six ZNF695 transcript variants are co-expressed in cancer cell lines. The amplicons were sequenced and identified. Additionally, we analyzed the expression of these six transcript variants in bone marrow from B-cell acute lymphoblastic leukemia patients and observed that ZNF695 transcript variants one and three were the predominant variants expressed in leukemia. Moreover, our results showed the co-expression of coding and long noncoding RNA. Finally, we observed that long noncoding RNA ZNF695 expression predicted survival rates.

30 December 2020 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
ACAlfredo Cabrera‐Cano
Alfredo Cabrera‐Cano
VDVíctor Manuel Dávila‐Borja
Víctor Manuel Dávila‐Borja
SJSergio Juárez-Méndez
Sergio Juárez-Méndez
JMJaime Marcial-Quino
Jaime Marcial-Quino
SGSaul Gomez-Manzo
Saul Gomez-Manzo
RCRosa Angélica Castillo-Rodríguez
Rosa Angélica Castillo-Rodríguez